Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis.

ABSTRACT:

Background

Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in patients with cirrhosis represent a significant therapeutic challenge as they are associated with poor outcomes due to high rates of treatment failure, and frequently induce liver decompensation.

Aims

To evaluate treatment failure and in-hospital mortality in two cohorts of patients with cirrhosis and with CRKP infections treated with antibiotic regimens including or excluding Ceftazidime-avibactam.

Methods

Data from hospitalized patients with liver cirrhosis and CRKP infections were extracted and retrospectively analyzed.

Results

During the study period, 39 cirrhotic patients with confirmed invasive CRKP infections were enrolled. Overall, the median age was 60 years with a median

SUBMITTER: Feldman S 

PROVIDER: S-EPMC9499843 | biostudies-literature | 2022 Sep-Oct

REPOSITORIES: biostudies-literature